Seattle, WA, June 8, 2021鈥� 密桃视频, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.
鈥淒avid comes to 密桃视频 with a wealth of leadership experience in drug development and business strategy,鈥� said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淗is extensive expertise in the biotech and biopharma sectors and proven track record of bringing novel oncology drugs from development all the way through to commercialization will be invaluable as we advance our in vivo cell therapies into the clinic.鈥�
Fontana joins 密桃视频 from Bristol Myers Squibb, where he was an executive in the Cell Therapy Franchise and part of the Lymphoma Disease Strategy Team. There, he led the development of CD19 CAR T cell therapy BREYANZI庐 from clinical evaluation to commercialization. Prior to this role, he led the advancement of late-stage immuno-oncology assets and translational medicine as Vice President of Immuno-Oncology at Pfizer. Fontana has successfully guided multiple drug candidates to significant milestones throughout his career, including ADCETRIS庐 (CD30 antibody-drug conjugate, Brentuximab vedotin), BAVENCIO庐 (avelumab, anti PD-L1), and relatlimab, (anti-LAG-3 antibody). Fontana received a Ph.D. in Pharmacology from Wayne State University and holds a PMP certification from the Project Management Institute.
鈥溍芴沂悠碘�檚 integrated in vivo platform approach to immunotherapy holds great potential to transform the current standard of cancer care by generating safe, broadly accessible immunotherapies that build off of the learnings of existing cell and gene therapy technologies,鈥� said David Fontana, Ph.D., Chief Business and Strategy Officer of 密桃视频. 鈥淚鈥檓 excited to join this forward-thinking team and help 密桃视频 deliver on the promise of our unique technologies to bring effective cancer treatments to patients in need.鈥�
About 密桃视频
密桃视频, Inc. is a pre-clinical stage company headquartered in Seattle, WA. Founded based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, 密桃视频 is advancing an entirely new approach to immunotherapy designed to retool a patient鈥檚 immune system in vivo. 密桃视频鈥檚 novel approach is powered by integrated cellular immunotherapy technologies comprising VivoVec in vivo delivery platform, the RACR in vivo cell expansion platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms create and harness a powerful immune response in the body to directly, safely and controllably attack cancer. 密桃视频 believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit .
###
Media Contact:
Marites Coulter
Verge Scientific Communications
mcoulter@vergescientific.com
+1 415.819.2214